Scientific understanding of COVID-19 is also changing so quickly that it makes sense to keep options open. Up to 90% of new entrants into clinical trials never make it to approval, and so investigators want to have as many shots on goal as possible. There are good reasons to build up a full pipeline of COVID-19 drugs. “Do we need 300 trials? Is that a good use of resources?” asks Daniel Bausch, director of the UK Public Health Rapid Support Team and infectious disease expert at the London School of Hygiene & Tropical Medicine. A further 150 trials are preparing to recruit patients.įor pandemic preparedness experts, this begs crucial questions. In the months since COVID-19 has spread, researchers have launched more than 180 clinical trials of everything from repurposed antivirals and immunomodulators to unproven cell therapies and vitamin C. But its rate of expansion is nevertheless cause for pause. The coronavirus disease 2019 (COVID-19) drug pipeline is not growing at quite the same speed as the pandemic. But do we really need so many trials? Asher Mullard reports. The world is rushing to test potential COVID-19 treatments.
0 Comments
Leave a Reply. |